ストックスクリーナーアプリを入手
3.20
4.92%
0.15
アフターアワーズ：
3.05
-0.15
-4.69%
前日終値:
$3.05
開ける：
$3.04
24時間の取引高:
82,702
Relative Volume:
1.07
時価総額：
$74.38M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-18.99%
1か月 パフォーマンス:
-25.93%
6か月 パフォーマンス:
-61.17%
1年 パフォーマンス:
-54.61%
1日の値動き範囲:
$2.90
$3.22
1週間の範囲:
$2.73
$4.44
52週間の値動き範囲:
$2.73
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Compare ACTU vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
3.20 | 70.89M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-26 | 開始されました | B. Riley Securities | Buy |
| 2025-04-22 | 開始されました | Craig Hallum | Buy |
| 2025-03-17 | 開始されました | H.C. Wainwright | Buy |
Actuate Therapeutics Inc (ACTU) 最新ニュース
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - Bitget
Actuate Therapeutics, Inc. Announces Presentation at Citizens Life Sciences Conference in Miami Beach - Quiver Quantitative
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - GlobeNewswire Inc.
ACTUActuate Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
ACTU Technical Analysis & ETF Price Forecast - Intellectia AI
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Actuate Therapeutics, Inc. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 - Quiver Quantitative
Is Actuate Therapeutics Inc. stock undervalued right nowMarket Performance Report & Daily Stock Trend Watchlist - mfd.ru
ACTU PE Ratio & Valuation, Is ACTU Overvalued - Intellectia AI
Is Actuate Therapeutics Inc. stock risky to hold nowPortfolio Update Report & Technical Confirmation Trade Alerts - mfd.ru
A | Will SIMAU announce a stock splitJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6%Here's What Happened - MarketBeat
What is the long term forecast for GATES GROUP Inc. stockJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Published on: 2026-02-07 16:03:44 - baoquankhu1.vn
Actuate Therapeutics registers 1.33M shares for resale by investors - MSN
Patterns Watch: Is Actuate Therapeutics Inc benefiting from innovation trendsJuly 2025 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Decliners Report: Is Actuate Therapeutics Inc benefiting from innovation trendsBreakout Watch & Daily Profit Maximizing Tips - baoquankhu1.vn
Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics - Clinical Leader
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt - Yahoo Finance
Sectors Review: Will Actuate Therapeutics Inc stock benefit from M AJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Actuate Therapeutics plans phase 1/2 trial of oral cancer drug - Investing.com Nigeria
Aug EndMonth: Whats the beta of PHGE stockJuly 2025 Chart Watch & Verified Entry Point Detection - baoquankhu1.vn
Actuate Therapeutics, Inc. Announces Initiation of Phase 1/2 Clinical Trial for Elraglusib Tablet in Advanced Cancers - Quiver Quantitative
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers - manilatimes.net
Actuate Therapeutics Announces Plans to Expand Clinical - GlobeNewswire
Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers - TradingView
Actuate Therapeutics, Inc. (NASDAQ:ACTU) Sees Significant Growth in Short Interest - MarketBeat
Risk Report: Why is VNCE stock going down2025 Technical Patterns & Detailed Earnings Play Strategies - baoquankhu1.vn
Merger Talk: Is Actuate Therapeutics Inc stock undervalued right nowInflation Watch & Fast Moving Stock Trade Plans - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Actuate Therapeutics (NASDAQ:ACTU) Downgraded by Wall Street Zen to “Sell” - Defense World
Is Actuate Therapeutics Inc stock showing strong momentumPortfolio Return Report & Capital Protection Trade Alerts - baoquankhu1.vn
Actuate Therapeutics, Inc. (ACTU) Receives a Buy from Craig-Hallum - The Globe and Mail
Market Wrap: Does Actuate Therapeutics Inc have consistent dividend growth2025 Price Targets & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Published on: 2026-01-16 10:23:54 - baoquankhu1.vn
Published on: 2026-01-16 07:35:07 - baoquankhu1.vn
H.C. Wainwright reiterates Buy rating on Actuate Therapeutics stock at $20 - Investing.com UK
Price Action: Is Actuate Therapeutics Inc stock risky to hold nowPortfolio Gains Summary & Consistent Growth Equity Picks - baoquankhu1.vn
Quarterly Recap: Can Actuate Therapeutics Inc stock deliver consistent earnings growthJuly 2025 WrapUp & Smart Money Movement Tracker - Bộ Nội Vụ
Actuate Therapeutics reports positive Phase 2 pancreatic cancer data - TipRanks
Actuate Therapeutics IncReports positive phase 2 trial data for elraglusibSEC filing - marketscreener.com
Actuate Therapeutics, Inc. Reports Positive Phase 2 Trial Results for Elraglusib - TradingView — Track All Markets
Actuate Therapeutics Reports Positive Phase 2 Study Results for Elraglusib Combination in Metastatic Pancreatic Cancer - Quiver Quantitative
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at AS - GlobeNewswire
Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ... - Sahm
Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock - Defense World
Will Actuate Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Why Actuate Therapeutics Inc. stock is recommended by analysts2025 Pullback Review & Weekly Return Optimization Alerts - Улправда
Can Actuate Therapeutics Inc. stock sustain market leadershipJuly 2025 Final Week & Weekly Breakout Watchlists - Улправда
Insider at Actuate Therapeutics Makes a Major Move With Fresh Stock Sale - TipRanks
Actuate therapeutics director Kairos Venture Partners II, L.P. sells $1.6m in shares - Investing.com Nigeria
Actuate Therapeutics Inc (ACTU) 財務データ
Actuate Therapeutics Inc (ACTU) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):